Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. NCNA.NASDAQ

NuCana PLC (NCNA NASDAQ) stock market data APIs

$3.63 -0.17(-4.5%) as of July 26, 2024
Price chart is built with Anychart

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

NuCana PLC Financial Data Overview

3.8
3.63
-
3.87
3.39
2.53-20.5
8 076 K
2 246 K
0
-3.25
0.994
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NCNA',
Type: 'Common Stock',
Name: 'NuCana PLC',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00HMJNMV8',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: '2017-09-28',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'ADR',
IsDelisted: false,
}

NuCana PLC Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -30 651 000
  • Earnings Per Share -16.49
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get NuCana PLC Earnings via APIs

  • Latest Release 2024-05-16
  • EPS/Forecast -276.55

Get NuCana PLC End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get NuCana PLC latest news via APIs

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Data Pipeline Continues to Advance with Data Updates Expected for all Programs in 2024 Well Capit...
  • EARNINGS RELEASES AND OPERATING RESULTS
  • NASDAQ:NCNA
  • NUCANA PLC

NuCana Announces Listing Transfer to Nasdaq Capital Market

EDINBURGH, United Kingdom, Nov. 10, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced today that it has received approval from Listing Qualifications D...
  • NASDAQ:NCNA
  • NUCANA PLC
  • STOCK MARKET NEWS
  • TRADING INFORMATION
Do you have any questions?
support@eodhistoricaldata.com